MDS and secondary AML: an evolutionary perspective.
Audeh
M W
MW
University of California, Los Angeles, Division of Hematology/Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
D000208:Acute Disease; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001711:Biotransformation / Q000235:genetics; D001854:Bone Marrow Cells / Q000473:pathology; D002470:Cell Survival; D002999:Clone Cells / Q000473:pathology; D018450:Disease Progression; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D006801:Humans; D007239:Infections / Q000150:complications; D007951:Leukemia, Myeloid / Q000209:etiology / Q000235:genetics / Q000473:pathology*; D008954:Models, Biological; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D014411:Neoplastic Stem Cells / Q000473:pathology; D011289:Preleukemia / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D012641:Selection, Genetic; D015262:Xenobiotics / Q000009:adverse effects
D000970:Antineoplastic Agents; D015262:Xenobiotics